On this page
When do you use Form FDA 3542a rather than Form 3542?
Use 3542a for patent information concerning a proposed product or use in a pending NDA, amendment or applicable supplement. Use 3542 for information concerning an approved product or use. Determine the relevant approval state, qualifying patent claims, labeling and submission trigger before completing the form; approval of a base NDA does not approve every supplemental use.
Before you begin
NDA patent-information submissions under 21 CFR 314.53, including applicable supplements. This is not an ANDA patent-certification or BLA patent-dispute guide.
What you will prepare: A claim-supported form package with timing, product scope and authorized declaration reviewed.
Choose by the approval status of the claimed product or use
Use Form 3542a for patent information accompanying a pending NDA, amendment or applicable supplement; use 3542 for information upon and after approval. The instructions call for separate forms for each patent. Establish the relevant product/use and application before selecting the form: an approved base NDA does not make an unapproved supplemental use approved.
Section 314.53 specifies timing and qualifying information, including the 30-day postapproval submission and timely filing of a newly issued patent within 30 days of issuance. Put the actual triggering event and deadline in the internal worklist. Do not calculate from the date the patent team happened to email the author.
Reconcile the consequential entries
Match the NDA and supplement, applicant/holder, product name, active ingredients, dosage form, route and strengths to the relevant application state. Verify patent number, issuance, expiration, owner and U.S. notice contact from controlled patent records. Do not infer expiration by adding a standard term to a filing date.
For drug-substance, drug-product and method-of-use entries, have counsel identify the qualifying claims. Map each submitted use to the proposed or approved labeling section and the claimed method; do not broaden a use description beyond the underlying claim and labeling. Assess exclusions and special cases in §314.53 rather than listing every patent in the portfolio. The declaration is a factual/legal attestation, not a field an author may sign for convenience.
Submit to the NDA and preserve the listing evidence
The instructions direct submission to the NDA, not directly to Orange Book staff, and say not to send a copy of the patent as the routine form submission. Have the regulatory publisher use the current electronic process. Retain the submitted form and receipt, then reconcile FDA’s published listing as appropriate; do not label information “listed” merely because it was sent.
Fictional exercise: the patent form describes an approved use more broadly than the approved label. Return the use mapping for counsel and regulatory review before declaration. If the supplement is still pending, reassess the form and proposed-label references. The June 2026 Q&A remains draft; its freshness does not supersede the regulation or turn proposed recommendations into final rules.
Review the patent, application and labeling together
Build a review sheet for each patent before completing its form. Counsel supplies the claim assessment; regulatory and labeling owners reconcile it with the application. The sheet is an internal preparation aid.
| Relationship | Record to reconcile | Stop and resolve when |
|---|---|---|
| Patent to application | Patent identifier, NDA and relevant supplement | The product or use cannot be tied to the application |
| Claim to category | Drug substance, drug product or method-of-use assessment | The request lists a portfolio without evaluating eligible claims |
| Use to labeling | Specific claim and corresponding proposed or approved label section | The description is broader than the claimed and relevant use |
| Form to state | Approval evidence for the particular product/use | A pending supplemental indication is described as already approved |
| Timing to event | Relevant approval, issuance or other applicable trigger | The tracker starts from internal receipt instead of the governing event |
| Filing to record | Executed form, submission evidence and later listing check | “Submitted” and “listed” are being used as the same status |
Postapproval exercise: a team previously supplied 3542a with the pending application and assumes the task is closed after approval. Reassess the postapproval 3542 submission under §314.53 and reconcile its entries with the actual approved product and labeling. Do not simply rename the earlier PDF: the approval-state review is the substantive step.
The instructions also distinguish a separate form for each patent from the additional sections within a form. Keep the patent identity fixed while reconciling the relevant product/use details. The official instruction PDFs inspected here retain 11/19 for 3542a and 11/16 for 3542; older revision dates alone do not authorize substituting an unofficial template.
Route noninfringement questions to the ANDA/505(b)(2) certification guide, and keep an exclusivity claim as a separate task. The June 2026 patent-form Q&A remains draft and not for implementation; use its stated status when recording the source basis for a decision.
Your preparation checklist
0/4 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Does submitting Form 3542a before approval eliminate the postapproval Form 3542 task?
No. The regulation and instructions distinguish patent information at filing from information upon and after approval. Assess the applicable postapproval submission and reconcile it with the approved product and labeling. A prior 3542a submission should not be treated as proof that the later task is complete.
Should the patent information form be sent directly to Orange Book staff?
The instructions direct submission to the NDA, rather than directly to Orange Book staff. Use the appropriate current submission process and retain the executed version and receipt. Check any subsequent listing separately; successful delivery does not by itself establish that the listing is correct.
Should every patent in the company’s portfolio be submitted for Orange Book listing?
No. Section 314.53 defines qualifying drug-substance, drug-product and method-of-use patents and excludes categories such as process, packaging, metabolite and intermediate patents. Have counsel assess the actual claims against the relevant product or use; the portfolio’s commercial importance is not the eligibility test.
Is the June 2026 guidance on Forms 3542a and 3542 final?
No. FDA’s page inspected for this review labels the June 2026 Q&A as draft and not for implementation. Keep that status explicit and use the regulation and applicable form instructions for the current requirements. A more recent publication date does not make a draft final.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Regulation
21 CFR Part 314: drug marketing applications ↗Current part reopened September 22, 2026; §§314.50, 314.53, 314.65, 314.72, 314.94, 314.99, 314.108 and 314.150–162 inspected. Not a general BLA rule.
Form instructions
FDA Form 3542a instructions ↗Instructions footer revision 11/19; pending NDA/amendment/supplement. PDF reopened September 22, 2026.
Form instructions
FDA Form 3542 instructions ↗Instructions footer revision 11/16; upon/after approval. PDF reopened September 22, 2026.
Draft guidance
Forms FDA 3542a and FDA 3542: Questions and Answers ↗June 2026 DRAFT, not for implementation. Status checked September 22; not treated as final authority.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 1.3.5.1. A heading identifies placement, not mandatory applicability.